凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
梅花生物(600873)公告正文

梅花生物:2015年第一季度报告

公告日期 2015-04-22
股票简称:梅花生物 股票代码:600873
                   2015 年第一季度报告
    公司代码:600873                         公司简称:梅花生物梅花生物科技集团股份有限公司
           2015 年第一季度报告
                         1 / 17
                            2015 年第一季度报告
                              目        录
    一、重要提示     ............................................................ 3二、公司主要财务数据和股东变化 ................................... 3
    三、重要事项     ............................................................ 6四、附录 .................................................................. 9
                                  2 / 17
                                         2015 年第一季度报告一、 重要提示1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,
    不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。1.2 公司全体董事出席董事会审议季度报告。1.3 公司负责人孟庆山、主管会计工作负责人李勇刚及会计机构负责人(会计主管人员)王爱玲
    保证季度报告中财务报表的真实、准确、完整。1.4 本公司第一季度报告未经审计。二、 公司主要财务数据和股东变化2.1 主要财务数据
                                                                            单位:元     币种:人民币
                                                                            本报告期末比上年度末增减
                         本报告期末                     上年度末
                                                                                       (%)
    总资产                 21,901,837,527.90                20,601,673,245.05                          6.31归属于上市公司股
                        8,397,853,280.54                 8,216,552,097.35                          2.21东的净资产
                       年初至报告期末          上年初至上年报告期末            比上年同期增减(%)经营活动产生的现
                          909,977,408.29                  -336,705,732.67                       370.26金流量净额
                       年初至报告期末          上年初至上年报告期末           比上年同期增减(%)
    营业收入                3,095,872,230.85                 2,099,058,041.30                        47.49归属于上市公司股
                          181,301,183.19                    75,105,641.06                       141.39东的净利润归属于上市公司股
    东的扣除非经常性          147,914,894.98                    36,275,301.83                       307.76损益的净利润
    加权平均净资产收                                                                                   增加
                                       2.18                          0.93
    益率(%)                                                                                1.25 个百分点基本每股收益(元/
                                       0.06                          0.02                           200股)稀释每股收益(元/
                                       0.06                          0.02                           200股)非经常性损益项目和金额√适用 □不适用
                                                                            单位:元     币种:人民币
                项目                           本期金额                           说明
    非流动资产处置损益                                   -396,691.62越权审批,或无正式批准文件,或偶发性的税收返还、减免计入当期损益的政府补助,但与公司正常
                                                    6,938,059.18经营业务密切相关,符合国家政策规定、
                                               3 / 17
                                       2015 年第一季度报告按照一定标准定额或定量持续享受的政府补助除外计入当期损益的对非金融企业收取的资金占用费企业取得子公司、联营企业及合营企业的投资成本小于取得投资时应享有被投资单位可辨认净资产公允价值产生的收益非货币性资产交换损益
    委托他人投资或管理资产的损益                     24,739,726.03因不可抗力因素,如遭受自然灾害而计提的各项资产减值准备债务重组损益企业重组费用,如安置职工的支出、整合费用等交易价格显失公允的交易产生的超过公允价值部分的损益同一控制下企业合并产生的子公司期初至合并日的当期净损益与公司正常经营业务无关的或有事项产生的损益除同公司正常经营业务相关的有效套期保值业务外,持有交易性金融资产、交易
    性金融负债产生的公允价值变动损益,以                  879,157.93及处置交易性金融资产、交易性金融负债和可供出售金融资产取得的投资收益单独进行减值测试的应收款项减值准备转回对外委托贷款取得的损益采用公允价值模式进行后续计量的投资性房地产公允价值变动产生的损益根据税收、会计等法律、法规的要求对当期损益进行一次性调整对当期损益的影响受托经营取得的托管费收入除上述各项之外的其他营业外收入和支
                                                  2,178,188.56出其他符合非经常性损益定义的损益项目
    少数股东权益影响额(税后)                            164,160.62
    所得税影响额                                     -1,116,312.49
               合计                              33,386,288.21
                                             4 / 17
                                             2015 年第一季度报告2.2 截止报告期末的股东总数、前十名股东、前十名流通股东(或无限售条件股东)持股情况表
                                                                                                           单位:股
    股东总数(户)                                                                                                 120887
                                              前十名股东持股情况
                              期末持股        比例    持有有限售条             质押或冻结情况
    股东名称(全称)                                                                                        股东性质
                                数量          (%)      件股份数量           股份状态            数量
    孟庆山                      854,103,033      27.48                  0            质押     654,590,000      境内自然人
    胡继军                      319,390,000      10.28                  0            质押     319,390,000      境内自然人
    香港鼎晖生物科技有限公司    120,125,120       3.86                  0              无                  0    境外法人建信基金公司-慧智投资 8
                              99,279,338      3.19                  0              无                  0      其他号结构化集合资金信托计划
    杨维永                        78,810,526      2.54                  0            质押         78,810,526   境内自然人
    王爱军                        71,316,274      2.29                  0            质押         71,316,274   境内自然人
    梁宇博                        53,668,518      1.73                  0            质押         53,668,518   境内自然人
    李宝骏                        31,080,000      1.00                  0            质押         31,080,000   境内自然人
    何君                          23,449,758      0.75                  0            质押         23,449,758   境内自然人
    张寿清                        20,000,000      0.64                  0              无                  0   境内自然人
                                         前十名无限售条件股东持股情况
    股东名称                                    持有无限售条件流通股的数                      股份种类及数量
                                                        量                             种类                 数量
    孟庆山                                                        854,103,033       人民币普通股               854,103,033
    胡继军                                                        319,390,000       人民币普通股               319,390,000
    香港鼎晖生物科技有限公司                                      120,125,120       人民币普通股               120,125,120
    建信基金公司-慧智投资 8 号结构化集合                          99,279,338                                  99,279,338
                                                                                人民币普通股资金信托计划
    杨维永                                                         78,810,526       人民币普通股               78,810,526
    王爱军                                                         71,316,274       人民币普通股               71,316,274
    梁宇博                                                         53,668,518       人民币普通股               53,668,518
    李宝骏                                                         31,080,000       人民币普通股               31,080,000
    何君                                                           23,449,758       人民币普通股               23,449,758
    张寿清                                                         20,000,000       人民币普通股               20,000,000
    上述股东关联关系或一致行动的说明           孟庆山、杨维永、王爱军、何君为一致行动人。备注:1.2013 年 12 月 30 日,孟庆山、杨维永、王爱军等五人,共同出具追加限售期的承诺函:其持有的公司股份自 2014年 1 月 2 日上市流通之日起追加限售锁定期 24 个月,即自 2014 年 1 月 2 日起 24 个月不上市交易或转让,限售期满后按照中国证监会或上海证券交易所的有关规定执行。2. 2015 年 4 月 16 日,胡继军先生将其质押给华创证券有限责任公司的 269,390,000 股流通股解除了质押登记。截止本报告出具日,胡继军先生持有公司股份 319,390,000 股,占公司股份总数的 10.28%;其中累计已质押股数50,000,000 股,占公司股本总数的 1.61%。2.3 截止报告期末的优先股股东总数、前十名优先股股东、前十名优先股无限售条件股东持股情
    况表□适用 √不适用
                                                     5 / 17
                                                2015 年第一季度报告三、 重要事项3.1 公司主要会计报表项目、财务指标重大变动的情况及原因√适用 □不适用资产负债表项:
                                                                                           单位:万元 币种:人民币
                            本报告期          上年度期                        增减幅
            项目                                               增减额                                差异说明
                                 末              末                           度(%)
                                                                                          主要系本期销售收入增加货款回
       货币资金             293,433.01       141,078.05      152,354.95        107.99
                                                                                          笼所致
    交易性金融资产           41,255.87                        41,255.87        100.00     本期购买理财产品
       应收票据              17,557.19          8,143.58        9,413.62       115.60     本期承兑收款增加所致
       预付账款              79,833.67       118,905.84       -39,072.17       -32.86     主要系本期预付玉米款减少所致
                                                                                          主要系本期子公司新疆梅花氨基
       在建工程              57,684.10       104,235.19       -46,551.09       -44.66     酸有限责任公司部分项目转固,
                                                                                          减少在建工程
                                                                                          主要系子公司新疆梅花氨基酸有
       工程物资                 1,791.26         888.77             902.49     101.54
                                                                                          限公司购进工程物资增加所致
                                                                                          主要系存货内部交易未实现利润
    递延所得税资产              1,087.07        2,855.17       -1,768.11       -61.93
                                                                                          影响递延所得税资产减少所致
                                                                                          主要系本期收回原委托渤海国际
    其他非流动资产                             23,002.15      -23,002.15      -100.00
                                                                                          信托有限公司进行投资的款项
                                                                                          本期应缴增值税及企业所得税增
       应交税费              10,992.81          4,601.92        6,390.89       138.87
                                                                                          加所致
                                                                                          主要系本期归还股东借款及归还
      其他应付款             56,377.46         83,307.62      -26,930.17       -32.33
                                                                                          通辽财政局借款所致
    一年内到期的非流动负                                         -199,829.5
                            190,679.98       390,509.57                        -51.17     本期偿还到期债券所致
             债                                                         9
    其他流动负债           244,647.29                       244,647.29        100.00     本期发行超短期融资券
      长期应付款             19,150.01                        19,150.01        100.00     本期新增融资租赁业务所致利润表项:
                                                                                           单位:万元 币种:人民币
                                                                        增减幅度
    项目            本报告期         上年同期             增减额                                    差异说明
                                                                         (%)
                                                                                        本期子公司新疆梅花氨基酸有限责
    营业收入          309,587.22        209,905.80        99,681.42           47.49      任公司产能释放导致销售收入增加
                                                                                        同时新增合并主体也带动收入增加
                                                                                        本期产能增加带动成本的增加以及
    营业成本          240,960.59        170,625.19        70,335.40           41.22
                                                                                        新增合并主体所致
    营业税金及附加           900.97              683.82         217.15           31.76      本期应交流转税增加
                                                                                        本期子公司新疆梅花氨基酸有限责
    销售费用           22,673.72            14,342.35       8,331.37          58.09      任公司产能增加,销售量增加,导
                                                                                        致运费增加
    管理费用           11,671.01             8,662.88       3,008.13          34.72      主要系本期新增合并主体所致
                                                                                        收到原委托渤海国际信托有限公司
    投资收益             2,407.97             172.00        2,235.97      1,299.99
                                                                                        进行投资的投资收益所致
    营业外收入             916.53             4,356.21     -3,439.68           -78.96     本期政府补贴减少所致
                                                         6 / 17
                                            2015 年第一季度报告
    营业外支出           44.57                3.35         41.22      1,232.50    本期固定资产处置损失增加所致
    所得税           5,112.56          2,265.84     2,846.72           125.64   本期利润总额增加所致
                                                                                本期子公司新疆梅花氨基酸有限责
                                                                                任公司产能释放,销量增加,同时
                                                                                氨基酸市场、味精市场逐步复苏,
    净利润          18,740.05          7,510.56    11,229.49           149.52
                                                                                公司主要产品味精、赖氨酸、苏氨
                                                                                酸等销售价格上涨带来利润的增
                                                                                加,以及本期理财收益增加所致。现金流量表项:
                                                                                   单位:万元 币种:人民币
             项目               本报告期    上年同期       增减额        增减幅度(%)          差异说明
                                                                                           本期销售收入增加货
    经营活动产生的现金流量净额      90,997.74   -33,670.57    124,668.31              370.26
                                                                                           款回笼增加所致
                                                                                           本期偿还债务及支付
    筹资活动产生的现金流量净额      39,563.20   64,580.40     -25,017.20              -38.74
                                                                                           利息增加所致3.2 重要事项进展情况及其影响和解决方案的分析说明√适用 □不适用1.公司债券发行事项为调整债务结构,补充日常营运资金,公司拟发行公司债券,发行规模不超过人民币 30 亿(含30 亿元),最终发行规模提请股东大会授权董事会根据公司资金需求情况和发行时市场情况,在上述范围内确定。该事项已经公司 2014 年度股东大会审议通过,尚需报中国证监会核准后方能实施。2.资产重组事项进展按照《中华人民共和国反垄断法》和《经营者集中申报办法》等相关规定要求,梅花生物作为申报义务人向商务部提交了经营者集中审查相关材料。2015 年 3 月 5 日,公司收到商务部反垄断局出具的商反垄立案函(2015)第 53 号通知函:根据《中华人民共和国反垄断法》第二十一条和《经营者集中申报办法》第十四条,现决定对梅花生物收购伊品生物 100%股权事宜予以立案并进入审查阶段。2015 年 4 月 3 日,公司收到商务部出具的《实施进一步审查通知》:根据《中华人民共和国反垄断法》第二十五条,经初步审查,现决定,对梅花生物科技集团股份有限公司收购宁夏伊品生物科技股份有限公司 100%股权案实施进一步审查。公司发行股份购买资产并募集配套资金相关事宜经中国证监会核准并商务部对本次交易的经营者集中审查通过后方可实施。3.2015 年第一季度业绩预增公告和实际业绩情况说明2015 年 4 月 9 日,公司发布了《2015 年第一季度业绩预增公告》(公告编号:2015-035),经财务初步测算,公司 2015 年第一季度实现归属于上市公司股东的净利润 1.8 亿元左右,与上年同期相比将增长 140%左右。实际归属上市公司股东的净利润为 18130 万元,和业绩预告数相比,差异不大。
                                                   7 / 17
                                        2015 年第一季度报告3.3 公司及持股 5%以上的股东承诺事项履行情况√适用 □不适用
                                                                     承诺时
              承诺                            承诺                                                 是否及时
    承诺背景              承诺方                                        间及期   是否有履行期限
              类型                            内容                                                 严格履行
                                                                       限
                                 在重组完成后,孟庆山先生及
                                 一致行动人将尽量避免与上市
                                 公司的关联交易,若有不可避
                                 免的关联交易,孟庆山先生及
                                 一致行动人与上市公司将依法       2010 年
    与重大资产            孟庆山及
             解决关              签订协议,履行合法程序,并       7 月 19
    重组相关的            其一致行                                                      否                是
             联交易              将按照有关法律、法规、《公       日出具
    承诺                  动人
                                 司章程》等有关规定履行信息         承诺
                                   披露义务和办理有关报批事
                                 宜。保证不通过关联交易损害
                                 上市公司及其他股东的合法权
                                              益。
                                 在本次交易完成后继续保持上
                                                                  2010 年
    与重大资产            孟庆山及   市公司的独立性,在资产、人
                                                                  7 月 19
    重组相关的    其他    其一致行   员、财务、机构、业务上遵循                         否                是
                                                                  日出具
    承诺                  动人   五分开原则,遵守中国证监会
                                                                    承诺
                                 有关规定,规范运作上市公司。
                                 在孟庆山先生及一致行动人作
                                 为上市公司控股股东或实际控
                                 制人之期限内,将采取有效措
                                                                  2010 年
    与重大资产            孟庆山及   施,并促使孟庆山先生或孟庆
             解决同                                               7 月 19
    重组相关的            其一致行   山先生及一致行动人下属控股                         否                是
             业竞争                                               日出具
    承诺                  动人   子公司采取有效措施,不会从
                                                                    承诺
                                 事或参与任何可能对上市公司
                                 或其控股子公司目前主要从事
                                   的业务构成竞争的业务。
                                   上述五人持有的公司股份自
                      股东孟庆   2014 年 1 月 2 日上市流通之日    24 个月,
                      山、杨维   起追加限售锁定期 24 个月,即     2014 年
    其他承诺     其他    永、王爱   自 2014 年 1 月 2 日起 24 个月   1月2日            是                是
                      军、何君、 不上市交易或转让,限售期满       -2016 年
                        杨维英   后按照中国证监会或上海证券       1月2日
                                   交易所的有关规定执行。3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重大变动的警
    示及原因说明□适用 √不适用
                                                          公司名称            梅花生物科技集团股份有限公司
                                                         法定代表人                       孟庆山
                                                              日期                       2015-4-21
                                               8 / 17
                                         2015 年第一季度报告四、 附录4.1 财务报表
                                    合并资产负债表
                                   2015 年 3 月 31 日编制单位:梅花生物科技集团股份有限公司
                                             单位:元            币种:人民币   审计类型:未经审计
                   项目                            期末余额                      年初余额流动资产:
    货币资金                                            2,934,330,078.13           1,410,780,531.53
    结算备付金
    拆出资金
    以公允价值计量且其变动计入当期损益的金融资产
    衍生金融资产                                          412,558,700.00
    应收票据                                              175,571,940.13              81,435,784.69
    应收账款                                              441,579,592.69             384,090,179.14
    预付款项                                              798,336,715.50           1,189,058,406.22
    应收保费
    应收分保账款
    应收分保合同准备金
    应收利息
    应收股利
    其他应收款                                            469,824,921.50             505,727,015.91
    买入返售金融资产
    存货                                                1,873,543,304.73           1,917,060,383.40
    划分为持有待售的资产
    一年内到期的非流动资产
    其他流动资产                                          389,966,226.21             473,086,939.60
      流动资产合计                                      7,495,711,478.89           5,961,239,240.49非流动资产:
    发放贷款及垫款
    可供出售金融资产                                      157,000,000.00             157,000,000.00
    持有至到期投资
    长期应收款
    长期股权投资                                           75,076,529.63              76,615,704.68
    投资性房地产
    固定资产                                        12,226,353,473.42             11,797,980,303.72
    在建工程                                              576,841,036.78           1,042,351,913.38
    工程物资                                               17,912,596.51               8,887,733.74
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                              908,547,221.24             865,500,541.28
    开发支出
    商誉                                                  433,524,530.32             433,524,530.32
                                               9 / 17
                                         2015 年第一季度报告
    长期待摊费用
    递延所得税资产                                        10,870,661.11       28,551,732.16
    其他非流动资产                                                           230,021,545.28
      非流动资产合计                                14,406,126,049.01     14,640,434,004.56
        资产总计                                    21,901,837,527.90     20,601,673,245.05流动负债:
    短期借款                                         5,557,632,293.83      5,011,769,533.28
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    以公允价值计量且其变动计入当期损益的金融负债
    衍生金融负债
    应付票据                                              50,000,000.00       43,000,000.00
    应付账款                                         1,031,572,379.22        867,949,855.60
    预收款项                                             339,041,444.79      372,200,472.73
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                                          52,765,676.21       59,444,446.79
    应交税费                                             109,928,072.79       46,019,214.45
    应付利息                                             140,969,141.17      139,428,338.31
    应付股利
    其他应付款                                           563,774,559.76      833,076,221.63
    应付分保账款
    保险合同准备金
    代理买卖证券款
    代理承销证券款
    划分为持有待售的负债
    一年内到期的非流动负债                           1,906,799,759.81      3,905,095,662.44
    其他流动负债                                     2,446,472,916.66
      流动负债合计                                  12,198,956,244.24     11,277,983,745.23非流动负债:
    长期借款                                             854,449,180.00      853,361,100.00
    应付债券
    其中:优先股
          永续债
    长期应付款                                           191,500,116.44
    长期应付职工薪酬
    专项应付款
    预计负债
    递延收益                                              65,182,891.85       65,577,951.03
    递延所得税负债                                        22,332,343.19       22,734,163.18
    其他非流动负债
      非流动负债合计                                 1,133,464,531.48        941,673,214.21
        负债合计                                    13,332,420,775.72     12,219,656,959.44所有者权益
                                               10 / 17
                                       2015 年第一季度报告
    股本                                           3,108,226,603.00               3,108,226,603.00
    其他权益工具
    其中:优先股
           永续债
    资本公积                                       2,240,485,918.58               2,240,485,918.58
    减:库存股
    其他综合收益
    专项储备
    盈余公积                                            224,074,848.34              224,074,848.34
    一般风险准备
    未分配利润                                     2,825,065,910.62               2,643,764,727.43
    归属于母公司所有者权益合计                     8,397,853,280.54               8,216,552,097.35
    少数股东权益                                        171,563,471.64              165,464,188.26
      所有者权益合计                               8,569,416,752.18               8,382,016,285.61
         负债和所有者权益总计                     21,901,837,527.90              20,601,673,245.05
    法定代表人:孟庆山          主管会计工作负责人:李勇刚会计机构负责人:王爱玲
                                   母公司资产负债表
                                   2015 年 3 月 31 日编制单位:梅花生物科技集团股份有限公司
                                               单位:元            币种:人民币 审计类型:未经审计
                     项目                              期末余额                  年初余额流动资产:
    货币资金                                               549,738,789.95             325,483,860.79
    以公允价值计量且其变动计入当期损益的金融资产
    衍生金融资产                                           184,000,000.00
    应收票据                                               129,900,500.40              17,151,070.98
    应收账款                                               215,223,628.04             180,327,599.35
    预付款项                                               279,124,479.24             809,763,519.50
    应收利息
    应收股利                                                                          300,000,000.00
    其他应收款                                           8,024,332,510.27           7,038,656,760.20
    存货                                                   264,537,644.34             429,976,073.97
    划分为持有待售的资产
    一年内到期的非流动资产
    其他流动资产                                            28,292,741.87              51,402,539.65
    流动资产合计                                       9,675,150,294.11           9,152,761,424.44非流动资产:
    可供出售金融资产                                       157,000,000.00             157,000,000.00
    持有至到期投资
    长期应收款
    长期股权投资                                         5,413,076,529.63           5,414,615,704.68
    投资性房地产
    固定资产                                               207,202,592.69             212,086,216.37
    在建工程
                                             11 / 17
                                       2015 年第一季度报告
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                                 71,550,264.92       42,751,078.98
    开发支出
    商誉
    长期待摊费用
    递延所得税资产                                            1,681,310.17        1,681,310.17
    其他非流动资产                                                              200,000,000.00
    非流动资产合计                                      5,850,510,697.41    6,028,134,310.20
      资产总计                                         15,525,660,991.52   15,180,895,734.64流动负债:
    短期借款                                              2,425,000,000.00    2,115,000,000.00
    以公允价值计量且其变动计入当期损益的金融负债
    衍生金融负债
    应付票据                                                 35,000,000.00       43,000,000.00
    应付账款                                              1,590,868,593.64    1,953,965,038.69
    预收款项                                                376,534,191.42      287,516,184.57
    应付职工薪酬                                              4,286,901.75        3,777,892.97
    应交税费                                                 19,751,035.18       13,367,869.02
    应付利息                                                130,911,543.26      129,562,019.97
    应付股利
    其他应付款                                               92,715,245.31      178,521,639.91
    划分为持有待售的负债
    一年内到期的非流动负债                                1,896,799,759.81    3,895,095,662.44
    其他流动负债                                          2,446,472,916.66
    流动负债合计                                        9,018,340,187.03    8,619,806,307.57非流动负债:
    长期借款                                                400,000,000.00      400,000,000.00
    应付债券
    其中:优先股
         永续债
    长期应付款
    长期应付职工薪酬
    专项应付款
    预计负债
    递延收益
    递延所得税负债
    其他非流动负债
    非流动负债合计                                        400,000,000.00      400,000,000.00
      负债合计                                          9,418,340,187.03    9,019,806,307.57所有者权益:
    股本                                                  3,108,226,603.00    3,108,226,603.00
    其他权益工具
                                             12 / 17
                                         2015 年第一季度报告
    其中:优先股
         永续债
    资本公积                                                2,208,701,622.94          2,208,701,622.94
    减:库存股
    其他综合收益
    专项储备
    盈余公积                                                  224,074,848.34            224,074,848.34
    未分配利润                                                566,317,730.21            620,086,352.79
    所有者权益合计                                        6,107,320,804.49          6,161,089,427.07
      负债和所有者权益总计                               15,525,660,991.52         15,180,895,734.64
    法定代表人:孟庆山            主管会计工作负责人:李勇刚会计机构负责人:王爱玲
                                            合并利润表
                                          2015 年 1—3 月编制单位:梅花生物科技集团股份有限公司
                                                   单位:元       币种:人民币   审计类型:未经审计
                       项目                                  本期金额               上期金额
    一、营业总收入                                              3,095,872,230.85        2,099,058,041.30
    其中:营业收入                                              3,095,872,230.85        2,099,058,041.30
      利息收入
      已赚保费
      手续费及佣金收入
    二、营业总成本                                              2,890,145,389.87        2,046,542,628.42
    其中:营业成本                                              2,409,605,892.70        1,706,251,901.13
      利息支出
      手续费及佣金支出
      退保金
      赔付支出净额
      提取保险合同准备金净额
      保单红利支出
      分保费用
      营业税金及附加                                             9,009,681.76           6,838,184.15
      销售费用                                                 226,737,227.25         143,423,508.43
      管理费用                                                 116,710,149.70          86,628,770.10
      财务费用                                                 128,082,438.46         103,400,264.61
      资产减值损失
    加:公允价值变动收益(损失以“-”号填列)
      投资收益(损失以“-”号填列)                            24,079,708.91           1,719,992.69
      其中:对联营企业和合营企业的投资收益                      -1,539,175.05             252,566.97
      汇兑收益(损失以“-”号填列)
    三、营业利润(亏损以“-”号填列)                             229,806,549.89          54,235,405.57
    加:营业外收入                                                 9,165,299.14          43,562,136.10
      其中:非流动资产处置利得                                      25,366.81              72,499.33
    减:营业外支出                                                   445,743.02              33,451.65
      其中:非流动资产处置损失                                     422,058.43
    四、利润总额(亏损总额以“-”号填列)                         238,526,106.01          97,764,090.02
                                               13 / 17
                                        2015 年第一季度报告
    减:所得税费用                                               51,125,639.44      22,658,448.96
    五、净利润(净亏损以“-”号填列)                            187,400,466.57      75,105,641.06
    归属于母公司所有者的净利润                                  181,301,183.19      75,105,641.06
    少数股东损益                                                  6,099,283.38六、其他综合收益的税后净额
    归属母公司所有者的其他综合收益的税后净额
    (一)以后不能重分类进损益的其他综合收益
       1.重新计量设定受益计划净负债或净资产的变动
       2.权益法下在被投资单位不能重分类进损益的其他综合收益中享有的份额
    (二)以后将重分类进损益的其他综合收益
       1.权益法下在被投资单位以后将重分类进损益的其他综合收益中享有的份额
       2.可供出售金融资产公允价值变动损益
       3.持有至到期投资重分类为可供出售金融资产损益
       4.现金流量套期损益的有效部分
       5.外币财务报表折算差额
       6.其他
    归属于少数股东的其他综合收益的税后净额
    七、综合收益总额                                              187,400,466.57      75,105,641.06
    归属于母公司所有者的综合收益总额                            181,301,183.19      75,105,641.06
    归属于少数股东的综合收益总额                                  6,099,283.38八、每股收益:
    (一)基本每股收益(元/股)                                             0.06               0.02
    (二)稀释每股收益(元/股)                                             0.06               0.02本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0 元,上期被合并方实现的净利润为: 0 元。
    法定代表人:孟庆山      主管会计工作负责人:李勇刚会计机构负责人:王爱玲
                                      母公司利润表
                                    2015 年 1—3 月编制单位:梅花生物科技集团股份有限公司
                                            单位:元 币种:人民币 审计类型:未经审计
                        项目                              本期金额             上期金额
    一、营业收入                                              1,996,601,436.60     1,304,332,311.86
    减:营业成本                                            1,909,233,574.71     1,204,096,622.22
       营业税金及附加                                             636,956.90
       销售费用                                               138,551,148.43      83,521,249.69
       管理费用                                                30,426,213.32      22,214,997.66
       财务费用                                                -3,118,542.86       2,357,529.74
       资产减值损失
    加:公允价值变动收益(损失以“-”号填列)
       投资收益(损失以“-”号填列)                          23,354,573.84         363,626.69
       其中:对联营企业和合营企业的投资收益                    -1,539,175.05         252,566.97
    二、营业利润(亏损以“-”号填列)                            -55,773,340.06      -7,494,460.76
                                                14 / 17
                                          2015 年第一季度报告
    加:营业外收入                                                   2,024,464.25            3,188,693.57
       其中:非流动资产处置利得                                         9,932.63                 5,540.02
    减:营业外支出                                                       19,746.77
       其中:非流动资产处置损失
    三、利润总额(亏损总额以“-”号填列)                           -53,768,622.58           -4,305,767.19
    减:所得税费用
    四、净利润(净亏损以“-”号填列)                               -53,768,622.58           -4,305,767.19五、其他综合收益的税后净额
    (一)以后不能重分类进损益的其他综合收益
    1.重新计量设定受益计划净负债或净资产的变动
    2.权益法下在被投资单位不能重分类进损益的其他综合收益中享有的份额
    (二)以后将重分类进损益的其他综合收益
    1.权益法下在被投资单位以后将重分类进损益的其他综合收益中享有的份额
    2.可供出售金融资产公允价值变动损益
    3.持有至到期投资重分类为可供出售金融资产损益
    4.现金流量套期损益的有效部分
    5.外币财务报表折算差额
    6.其他
    六、综合收益总额                                                 -53,768,622.58           -4,305,767.19七、每股收益:
    (一)基本每股收益(元/股)
    (二)稀释每股收益(元/股)
    法定代表人:孟庆山            主管会计工作负责人:李勇刚会计机构负责人:王爱玲
                                    合并现金流量表
                                    2015 年 1—3 月编制单位:梅花生物科技集团股份有限公司
                                            单位:元               币种:人民币    审计类型:未经审计
                      项目                                  本期金额                  上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                              3,219,586,903.33           1,696,557,674.32
    客户存款和同业存放款项净增加额
    向中央银行借款净增加额
    向其他金融机构拆入资金净增加额
    收到原保险合同保费取得的现金
    收到再保险业务现金净额
    保户储金及投资款净增加额
    处置以公允价值计量且其变动计入当期损益的金融资产净增加额
    收取利息、手续费及佣金的现金
    拆入资金净增加额
    回购业务资金净增加额
    收到的税费返还                                               18,312,791.84
                                                  15 / 17
                                       2015 年第一季度报告
    收到其他与经营活动有关的现金                            25,493,876.00        123,426,025.54
    经营活动现金流入小计                               3,263,393,571.17   1,819,983,699.86
    购买商品、接受劳务支付的现金                         1,634,892,536.50   1,719,945,150.89
    客户贷款及垫款净增加额
    存放中央银行和同业款项净增加额
    支付原保险合同赔付款项的现金
    支付利息、手续费及佣金的现金
    支付保单红利的现金
    支付给职工以及为职工支付的现金                         224,095,346.60        145,205,833.74
    支付的各项税费                                          87,325,692.62         40,822,538.71
    支付其他与经营活动有关的现金                           407,102,587.16        250,715,909.19
    经营活动现金流出小计                               2,353,416,162.88   2,156,689,432.53
      经营活动产生的现金流量净额                         909,977,408.29       -336,705,732.67二、投资活动产生的现金流量:
    收回投资收到的现金
    取得投资收益收到的现金                                  25,618,883.96          1,467,425.72
    处置固定资产、无形资产和其他长期资产收回                    29,710.00             60,000.00的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金                           200,000,000.00
    投资活动现金流入小计                                 225,648,593.96          1,527,425.72
    购建固定资产、无形资产和其他长期资产支付               143,771,674.90        136,930,883.21的现金
    投资支付的现金                                         412,558,700.00        128,500,000.00
    质押贷款净增加额
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金                             1,150,000.00        145,000,000.00
    投资活动现金流出小计                                 557,480,374.90        410,430,883.21
      投资活动产生的现金流量净额                        -331,831,780.94       -408,903,457.49三、筹资活动产生的现金流量:
    吸收投资收到的现金
    其中:子公司吸收少数股东投资收到的现金
    取得借款收到的现金                                   3,963,992,282.00   2,127,553,830.00
    发行债券收到的现金                                                      1,000,000,000.00
    收到其他与筹资活动有关的现金                           191,002,038.87
    筹资活动现金流入小计                               4,154,994,320.87   3,127,553,830.00
    偿还债务支付的现金                                   2,973,059,659.00   1,790,148,090.00
    分配股利、利润或偿付利息支付的现金                     138,284,803.42        111,782,494.97
    其中:子公司支付给少数股东的股利、利润
    支付其他与筹资活动有关的现金                           648,017,899.23        579,819,280.42
    筹资活动现金流出小计                               3,759,362,361.65   2,481,749,865.39
      筹资活动产生的现金流量净额                         395,631,959.22        645,803,964.61
    四、汇率变动对现金及现金等价物的影响                       6,274,141.39          4,229,331.89
    五、现金及现金等价物净增加额                             980,051,727.96        -95,575,893.66
    加:期初现金及现金等价物余额                           559,553,015.97        557,110,850.67
    六、期末现金及现金等价物余额                           1,539,604,743.93        461,534,957.01
    法定代表人:孟庆山         主管会计工作负责人:李勇刚会计机构负责人:王爱玲
                                             16 / 17
                                       2015 年第一季度报告
                                  母公司现金流量表
                                    2015 年 1—3 月编制单位:梅花生物科技集团股份有限公司
                                            单位:元          币种:人民币   审计类型:未经审计
                   项目                                本期金额                 上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                         1,999,434,753.42            969,765,509.35
    收到的税费返还
    收到其他与经营活动有关的现金                         1,530,986,320.87          1,181,603,301.56
    经营活动现金流入小计                               3,530,421,074.29          2,151,368,810.91
    购买商品、接受劳务支付的现金                         1,587,538,827.36            682,270,610.30
    支付给职工以及为职工支付的现金                          16,375,381.84              9,906,840.39
    支付的各项税费                                           2,856,837.05              3,483,302.16
    支付其他与经营活动有关的现金                         1,665,392,568.66          2,229,549,674.23
    经营活动现金流出小计                               3,272,163,614.91          2,925,210,427.08
      经营活动产生的现金流量净额                         258,257,459.38           -773,841,616.17二、投资活动产生的现金流量:
    收回投资收到的现金
    取得投资收益收到的现金                                 324,893,748.89                111,059.72
    处置固定资产、无形资产和其他长期资产收回                    20,000.00的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金                           200,000,000.00
    投资活动现金流入小计                                 524,913,748.89                111,059.72
    购建固定资产、无形资产和其他长期资产支付                31,344,020.00                242,679.00的现金
    投资支付的现金                                         184,000,000.00            -23,552,499.76
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金                             1,150,000.00            145,000,000.00
    投资活动现金流出小计                                 216,494,020.00            121,690,179.24
      投资活动产生的现金流量净额                         308,419,728.89           -121,579,119.52三、筹资活动产生的现金流量:
    吸收投资收到的现金
    取得借款收到的现金                                   2,892,295,000.00          1,570,000,000.00
    收到其他与筹资活动有关的现金                         1,905,000,000.00          1,491,000,000.00
    筹资活动现金流入小计                               4,797,295,000.00          3,061,000,000.00
    偿还债务支付的现金                                   2,132,295,000.00            671,000,000.00
    分配股利、利润或偿付利息支付的现金                     103,092,536.68             76,373,564.55
    支付其他与筹资活动有关的现金                         3,002,869,485.00          1,509,375,505.66
    筹资活动现金流出小计                               5,238,257,021.68          2,256,749,070.21
      筹资活动产生的现金流量净额                        -440,962,021.68            804,250,929.79
    四、汇率变动对现金及现金等价物的影响                          91,902.57                     0.27
    五、现金及现金等价物净增加额                             125,807,069.16            -91,169,805.63
    加:期初现金及现金等价物余额                            42,198,920.79            159,206,324.10
    六、期末现金及现金等价物余额                             168,005,989.95             68,036,518.47
    法定代表人:孟庆山         主管会计工作负责人:李勇刚会计机构负责人:王爱玲
                                             17 / 17
数据加载中...
prevnext
手机查看股票